CSIR-IMTECH’s KNOW-HOW FOR RECOMBINANT STAPHYLOKINASE
Impact of the Technology:
This agent (a biogeneric) has previously shown, promise as an improved clot-buster in clinical trials abroad.
Summary of the work:
A recombinant strain has been developed for high level intracellular production of Staphylokinase in E. coli.
A high-efficiency facile two step protocol for purification of staphylokinase has also been developed.
The complete technological package for the production for recombinant staphylokinase has been transferred to M/S Strides Arcolab Ltd., Bangalore.
The licensee is working on development of the commercial scale process with IMTECH’s advice at the pre-clinical testing stage.